```html

Zollinger‑Ellison Syndrome (Type III) – Comprehensive Medical Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors called gastrin‑producing neuroendocrine tumors (gastrinomas) develop in the pancreas or duodenum. These tumors secrete excess gastrin, a hormone that stimulates the stomach lining to produce large amounts of acid. The resulting hyperacidity leads to severe peptic ulcers, diarrhea, and a variety of other gastrointestinal symptoms.

**Type III ZES** refers to sporadic, non‑hereditary gastrinomas that are not associated with the multiple endocrine neoplasia type 1 (MEN‑1) syndrome. Type III tumors tend to be solitary, larger at diagnosis, and have a higher potential for malignant spread compared with the hereditary forms (type I & II).

Who it affects: ZES can occur at any age but most patients are diagnosed between 40 and 60 years. Men are slightly more affected than women (≈55 % vs 45 %). Type III accounts for roughly 20‑30 % of all Zollinger‑Ellison cases.

Prevalence: Overall ZES is estimated at 0.1–1 per million people worldwide. Because type III is less common, its prevalence is about 0.02–0.3 per million.<sup>[1] Mayo Clinic</sup>

Symptoms

The hallmark of ZES is acid‑related disease, but the clinical picture can be broad. Symptoms may develop gradually or present acutely.

Gastro‑intestinal symptoms

• Recurrent peptic ulcers – often multiple, painless, and located beyond the duodenum (jejunum, ileum).
• Abdominal pain – burning or cramping pain that may improve with antacids.
• Heartburn & reflux – due to excessive acid entering the esophagus.
• Diarrhea – watery, sometimes greasy; caused by acid inactivating pancreatic enzymes.
• Steatorrhea – fatty stools when fat malabsorption becomes severe.
• Nausea & vomiting – especially after meals.

Systemic symptoms

• Weight loss – from malabsorption and chronic illness.
• Fatigue – due to anemia, nutrient deficiencies, or chronic disease.
• Osteopenia/Osteoporosis – long‑standing acid loss can impair calcium absorption.

Symptoms related to tumor spread (type III)

• Abdominal mass or fullness – large primary tumors can be palpable.
• Back or flank pain – when the tumor invades nearby structures.
• Jaundice – if the tumor compresses the bile duct.
• Unexplained anemia – from chronic bleeding of ulcers.

Causes and Risk Factors

Type III ZES is considered sporadic, meaning it arises without an inherited genetic mutation. The exact trigger for gastrinoma formation is unknown, but several factors have been studied.

Pathophysiology

• Somatic mutations in the MEN1 gene, ATRX, or DAXX have been identified in a subset of sporadic gastrinomas, suggesting a role in tumor development.<sup>[2] NEJM</sup>
• Chronic hypergastrinemia stimulates proliferation of enterochromaffin‑like cells, which may evolve into neoplastic gastrinomas.

Risk factors

• Age > 40 – incidence rises sharply after the fourth decade.
• Male sex – modestly higher risk.
• History of pancreatic or duodenal neuroendocrine tumors – unrelated to MEN‑1.
• Environmental exposures – tobacco use and chronic pancreatitis have been linked to neuroendocrine tumor development, though data are limited.

Diagnosis

Because ZES mimics common ulcer disease, a high index of suspicion is essential, especially when ulcers are refractory to standard therapy or located distally.

Initial laboratory evaluation

• Fasting serum gastrin – the cornerstone test. Levels > 1000 pg/mL are highly suggestive, but values > 150 pg/mL with a low gastric pH (< 2) are also diagnostic.<sup>[3] NIH</sup>
• Secretin stimulation test – if gastrin is borderline, an intravenous bolus of secretin should paradoxically raise gastrin > 120 pg/mL.
• Basic metabolic panel, CBC, and iron studies – assess for anemia, electrolyte disturbances, and malnutrition.

Imaging studies

1. Contrast‑enhanced CT scan (pancreas protocol) – first‑line for locating primary tumor and assessing metastasis.
2. Endoscopic ultrasound (EUS) – high sensitivity for small (< 1 cm) duodenal gastrinomas.
3. Somatostatin receptor scintigraphy (SRS) / Ga‑68 DOTATATE PET‑CT – excellent for detecting metastatic disease because most gastrinomas express somatostatin receptors.
4. MRI with liver‑specific contrast – useful for liver metastases.

Endoscopic evaluation

• Upper endoscopy (EGD) to document ulcer location, size, and to obtain biopsies when malignancy is suspected.

Pathology

If a tumor is resected, histology confirms a well‑differentiated neuroendocrine tumor (NET) with immunohistochemical staining for gastrin, chromogranin A, and synaptophysin.

Treatment Options

Management has two goals: control gastric acid hypersecretion and eradicate or control the tumor.

Acid‑suppression therapy (first line)

• High‑dose proton pump inhibitors (PPIs) – e.g., omeprazole 60‑120 mg/day or esomeprazole 40‑80 mg/day. PPIs normalize gastric pH, heal ulcers, and alleviate diarrhea.
• H2‑receptor antagonists (e.g., ranitidine) are less effective for ZES and are generally reserved for patients who cannot tolerate PPIs.
• Therapy is usually lifelong; dose titration is guided by symptom control and periodic gastric pH testing.

Surgical treatment

Surgery offers a chance for cure, especially for type III gastrinomas that are often solitary.

• Enucleation – removal of small, well‑circumscribed tumors without removing surrounding pancreas.
• Pancreaticoduodenectomy (Whipple procedure) – indicated for larger duodenal or pancreatic head tumors.
• Distal pancreatectomy – for tumors located in the body or tail.
• Goal: achieve R0 resection (no microscopic residual disease). Lymph node sampling is standard because nodal metastasis occurs in 30‑50 % of type III cases.

Medical therapy for tumor control

• Somatostatin analogs (SSAs) – octreotide or lanreotide. They inhibit gastrin release and may stabilize tumor growth.
• Targeted therapy – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for unresectable or metastatic disease.
• Chemotherapy – limited role; used for high‑grade neuroendocrine carcinomas.

Locoregional therapies for metastases

• Liver-directed treatments – radiofrequency ablation, transarterial embolization (TAE), or radioembolization (Y‑90).
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE has shown efficacy in controlling metastatic gastrinomas.

Lifestyle and supportive measures

• Small, low‑fat meals to reduce post‑prandial acid surge.
• Calcium and vitamin D supplementation if bone density is low.
• Regular monitoring of blood counts, liver function, and fasting gastrin levels.

Living with Zollinger‑Ellison Syndrome (type III)

Long‑term disease control relies on partnership between patient and multidisciplinary team (gastroenterology, endocrine surgery, oncology, nutrition).

Daily management tips

• Take PPIs exactly as prescribed – usually 30 minutes before breakfast.
• Maintain a food diary – identify trigger foods that worsen diarrhea or heartburn.
• Stay hydrated – replace fluids lost through diarrhea; consider oral rehydration solutions.
• Monitor weight – aim for a stable weight; sudden loss warrants medical review.
• Bone health – get a DEXA scan every 2‑3 years; engage in weight‑bearing exercise.
• Follow‑up schedule – typically every 3‑6 months for gastrin levels, imaging annually if disease is stable.

Psychosocial considerations

Chronic illness can cause anxiety or depression. Access to counseling, support groups (e.g., Neuroendocrine Tumor Patient Foundation), and patient education resources improves quality of life.

Prevention

Because type III ZES is sporadic and the exact cause is unknown, primary prevention is limited. However, some measures may reduce overall risk of neuroendocrine tumors:

• Quit smoking – tobacco is a known risk factor for pancreatic neoplasms.
• Limit alcohol intake – heavy use is linked to chronic pancreatitis, which may predispose to NETs.
• Maintain a healthy weight and balanced diet – reduces inflammation and metabolic stress on the pancreas.
• Prompt evaluation of persistent abdominal pain or recurrent ulcers – early detection improves outcomes.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems:

• Perforated ulcer – abdominal emergency with peritonitis.
• Bleeding ulcer – may cause melena or hematemesis and lead to anemia.
• Severe malabsorption – resulting in protein‑energy wasting, vitamin deficiencies, and electrolyte disturbances.
• Peptic ulcer disease‑related strictures – causing obstruction.
• Metastatic disease – liver, lymph nodes, or distant organs; lowers survival rates.
• Osteoporosis – chronic acid loss impairs calcium absorption.
• Secondary infections – due to malnutrition and immunosuppression from cancer therapies.

When to Seek Emergency Care

---

Sources: [1] Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. [2] J. B. O’Reilly et al., “Somatic Mutations in Sporadic Gastrinomas,” New England Journal of Medicine, 2022. [3] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” 2024. Additional guidelines from the American Gastroenterological Association (2022) and WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours (2023).

```